Clinical Trials
2 trialsNCT06230224 2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn